Document is current
Any future updates will be listed below
-
Authors
Luo, Rui
Zhao, Zhenyu
Zhang, Chuan
Li, Ru-Shuai
Wang, Yanrong
Meng, Qingle
Ni, Yudan
Wang, Bolin
Li, Lanhua
Feng, Luan
Yang, Rui
Xie, Lin
Chen, Xin
Zhang, Ming-Rong
Wang, Feng https://orcid.org/0000-0003-1089-3095
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05867589 at ClinicalTrials.govDocuments that mention this clinical trial
Evaluation of myocardial fibrosis and wall motion abnormality with 68Ga-FAPI PET/MR in coronary heart disease
https://doi.org/10.1186/s13550-025-01246-2
-
Funding
Funding for this research was provided by:
Jiangsu Provincial Medical Key Discipline Cultivation Unit (JSDW202247)
Jiangsu Provincial Key Research and Development Special Fund (BE2017612)
Nanjing Medical and Health International Joint Research and Development Project (201911042)
General Project of Science and Technology Development Fund of Nanjing Medical University (NMUB2019154)
National Natural Science Foundation of China (82003532)
Nuclear Medicine Laboratory Open Project (2021HYX009)
the second round of Nanjing Clinical Medical Center
Japan China Sasakawa Medical Fellowship
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 25 April 2025
First Online: 21 July 2025
Declarations
:
: This prospective study was approved by the institutional Ethics Committee of Nanjing First Hospital (identification no. KY20230428-02) and was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent.
: Not applicable.
: The authors declare that they have no competing interests.
